Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Terns Pharmaceuticals Inc (TERN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
02/23/2026: TERN (3-star) is a STRONG-BUY. BUY since 3 days. Simulated Profits (3.57%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $58.11
1 Year Target Price $58.11
| 5 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.27B USD | Price to earnings Ratio - | 1Y Target Price 58.11 |
Price to earnings Ratio - | 1Y Target Price 58.11 | ||
Volume (30-day avg) 9 | Beta -0.28 | 52 Weeks Range 1.86 - 48.26 | Updated Date 02/23/2026 |
52 Weeks Range 1.86 - 48.26 | Updated Date 02/23/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.02 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -19.94% | Return on Equity (TTM) -29.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 388401715 | Price to Sales(TTM) 302.64 |
Enterprise Value 388401715 | Price to Sales(TTM) 302.64 | ||
Enterprise Value to Revenue 337.47 | Enterprise Value to EBITDA -5.8 | Shares Outstanding 108767281 | Shares Floating 85201961 |
Shares Outstanding 108767281 | Shares Floating 85201961 | ||
Percent Insiders 0.6 | Percent Institutions 118.81 |
Upturn AI SWOT
Terns Pharmaceuticals Inc
Company Overview
History and Background
Terns Pharmaceuticals Inc. was founded in 2017 with a focus on developing innovative treatments for non-alcoholic steatohepatitis (NASH) and other metabolic diseases. The company has advanced several drug candidates through preclinical and early clinical stages, aiming to address significant unmet medical needs in these therapeutic areas. Key milestones include the initiation of clinical trials for its lead candidates and strategic partnerships.
Core Business Areas
- NASH and Metabolic Diseases: Terns Pharmaceuticals is dedicated to developing therapies for NASH and other metabolic and fibrotic diseases. Their pipeline primarily consists of small molecule drug candidates designed to target key pathways involved in liver disease progression.
Leadership and Structure
Terns Pharmaceuticals Inc. is led by a management team with extensive experience in drug development and the pharmaceutical industry. The organizational structure is typical of a biotechnology company, with departments focused on research and development, clinical operations, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- TERN-101: TERN-101 is a THR-u03b2 (thyroid hormone receptor beta) agonist developed by Terns Pharmaceuticals for the treatment of NASH. It is currently in clinical development, with the aim of improving liver inflammation and fibrosis. Competitors in this space include companies developing other THR-u03b2 agonists and drugs targeting different pathways in NASH. Specific market share data for TERN-101 is not yet available as it is still in clinical trials.
- TERN-201: TERN-201 is an ASC (apoptosis speck like protein containing a CARD) inhibitor in development for NASH and other fibrotic diseases. Like TERN-101, it is in clinical trials, and specific market share data is not yet applicable. Competitors include other companies exploring inflammasome pathways for liver diseases.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the segment focused on liver diseases like NASH, is characterized by significant unmet medical needs and a growing market potential. Research and development are intensive, with numerous companies vying to bring effective therapies to market. Regulatory pathways are complex, and clinical trial success is critical.
Positioning
Terns Pharmaceuticals positions itself as a developer of novel, small-molecule therapies targeting key drivers of NASH and metabolic diseases. Their differentiated approach aims to offer significant clinical benefits. Their competitive advantage lies in their targeted drug candidates and focus on specific pathways.
Total Addressable Market (TAM)
The total addressable market for NASH therapies is projected to be in the tens of billions of dollars globally. Terns Pharmaceuticals is positioned to capture a portion of this market with its pipeline candidates if they achieve regulatory approval and demonstrate efficacy and safety.
Upturn SWOT Analysis
Strengths
- Focus on a significant unmet medical need (NASH and metabolic diseases).
- Pipeline of differentiated small molecule drug candidates.
- Experienced management team in drug development.
- Potential for novel mechanisms of action.
Weaknesses
- Early-stage clinical development for key assets.
- Limited financial resources compared to larger pharmaceutical companies.
- Reliance on successful clinical trial outcomes.
- Market competition from established and emerging players.
Opportunities
- Growing prevalence of NASH and metabolic diseases.
- Potential for strategic partnerships and collaborations.
- Advancements in understanding liver disease biology.
- Emergence of new diagnostic tools for NASH.
Threats
- Clinical trial failures or delays.
- Intense competition and rapid innovation in the field.
- Stringent regulatory approval processes.
- Challenges in market access and reimbursement.
- Potential for adverse events in late-stage trials.
Competitors and Market Share
Key Competitors
- Madrigal Pharmaceuticals (MDGL)
- Intercept Pharmaceuticals (ICPT)
- Viking Therapeutics (VKTX)
- Galectin Therapeutics (GALT)
Competitive Landscape
Terns Pharmaceuticals faces strong competition in the NASH space. While companies like Madrigal and Intercept have approved or late-stage therapies, Terns aims to differentiate with novel mechanisms of action and potentially improved safety/efficacy profiles. Their advantage lies in their focused pipeline, but they face the challenge of competing against more established players with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Terns Pharmaceuticals' growth trajectory has been marked by the progression of its drug candidates through preclinical and early clinical development phases. This growth is fueled by scientific advancement and strategic financing rounds.
Future Projections: Future growth projections are highly dependent on the successful clinical development and eventual market approval of its pipeline assets. Analyst estimates would focus on potential peak sales if the drugs are commercialized successfully.
Recent Initiatives: Recent initiatives likely involve advancing TERN-101 and TERN-201 through their respective clinical trial phases, potentially exploring new indications, and seeking strategic partnerships to accelerate development and commercialization.
Summary
Terns Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing treatments for NASH and metabolic diseases. Its strengths lie in its targeted pipeline and experienced management, while weaknesses include its early stage and reliance on clinical success. The company has opportunities in a growing market but faces significant threats from competition and regulatory hurdles. Continued progress in clinical trials and successful financing will be crucial for its future.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (e.g., 10-K, 10-Q)
- Financial News Outlets (e.g., Bloomberg, Reuters)
- Industry Analyst Reports
- Company Investor Relations Materials
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Stock market investments are subject to risk, and investors should conduct their own due diligence before making any investment decisions. Market share data is estimated and may not be precise. Financial performance metrics for clinical-stage companies differ significantly from revenue-generating businesses.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Terns Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Foster City, CA, United States | ||
IPO Launch date 2021-02-05 | CEO & Director Ms. Amy L. Burroughs M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website https://www.ternspharma.com |
Full time employees 59 | Website https://www.ternspharma.com | ||
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.